Advertisement

Journal of General Internal Medicine

, Volume 34, Issue 11, pp 2637–2642 | Cite as

The Stage IV Shuffle: Elusiveness of Straight Talk About Advanced Cancer

  • Donald A. BrandEmail author
Perspective

Abstract

During the initial consultation with a patient to communicate a diagnosis of late-stage cancer, the oncologist may refrain from giving survival statistics, redirecting the conversation from the bad news (incurability) to the practical aspects of the patient’s care (treatments, timetables, appointments, and testing to monitor response to treatment). Whether conscious or unconscious, this diversion helps cushion the impact of the disturbing news. This paper shows that clinicians’ gingerly handling of harsh facts when they talk with patients also applies to health educators and researchers when they write about late-stage cancer. As a result, these cancer patients typically lack an understanding of their poor prognosis and the limited effectiveness of most available treatments, possibly compromising their ability to make informed choices. To remedy this problem, I describe an approach to straight talk about late-stage cancer that can give a patient realistic hopes instead of false hopes that are apt to betray later on. I also propose an enhanced method of displaying and interpreting comparative efficacy data that can facilitate understanding and serve as a basis for shared decision making.

KEY WORDS

cancer communication patient engagement ethics 

Notes

Acknowledgments

I am grateful to Albert B. Lowenfels, MD, Jeffrey T. Berger, MD, and Melissa J. Fazzari, PhD, for their guidance in the formulation of the manuscript, and to Thomas M. Jeitner, PhD, and Allison B. Reiss, MD, for critiquing multiple drafts. I also thank reviewers for their detailed comments, which helped improve the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The author declares that he does not have a conflict of interest.

References

  1. 1.
    The AM, Hak T, Koeter G, van Der Wal G. Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ. 2000;321:1376–81.CrossRefGoogle Scholar
  2. 2.
    Raskin W, Harle I, Hopman WM, Booth CM. Prognosis, treatment benefit and goals of care: What do oncologists discuss with patients who have incurable cancer? Clin Oncol (R Coll Radiol). 2016;28:209–14.CrossRefGoogle Scholar
  3. 3.
    Weeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–25.CrossRefGoogle Scholar
  4. 4.
    Thorne S, Hislop TG, Kuo M, Armstrong EA. Hope and probability: patient perspectives of the meaning of numerical information in cancer communication. Qual Health Res. 2006;16:318–36.CrossRefGoogle Scholar
  5. 5.
    The Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, National Institutes of Health. Relative survival by stage (2008–2014). Available at: https://seer.cancer.gov/canques/survival.html. Accessed May 24, 2019.
  6. 6.
    American Cancer Society. Available at: https://www.cancer.org/. Accessed May 24, 2019.
  7. 7.
    National Cancer Institute, National Institutes of Health. Available at: https://www.cancer.gov/about-cancer. Accessed May 24, 2019.
  8. 8.
    Susan G. Komen. Available at: https://ww5.komen.org. Accessed May 24, 2019.
  9. 9.
  10. 10.
    Audrey S, Abel J, Blazeby JM, Falk S, Campbell R. What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study. BMJ. 2008;337:a752.CrossRefGoogle Scholar
  11. 11.
    Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists’ attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol. 2002;20:2189–96.CrossRefGoogle Scholar
  12. 12.
    de Haes H, Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns. 2003;50:43–9.CrossRefGoogle Scholar
  13. 13.
    Susan G. Komen. Available at: https://ww5.komen.org/LivingWithStageIVBreastCancer.html. Accessed May 24, 2019.
  14. 14.
    Liu CY, Chen WT, Kung PT, et al. Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program. BMC Cancer. 2014;14:446.CrossRefGoogle Scholar
  15. 15.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.CrossRefGoogle Scholar
  16. 16.
    Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000;321:531–5.Google Scholar
  17. 17.
    Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(1 Suppl):226S–243S.CrossRefGoogle Scholar
  18. 18.
    Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug’s effect while administered and is not a surrogate for overall survival. Cancer J. 2009;15:379–85.CrossRefGoogle Scholar
  19. 19.
    Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009;15:401–5.CrossRefGoogle Scholar
  20. 20.
    Cancer Facts & Figures – 2018, American Cancer Society (ACS), Atlanta, Georgia, 2018. Available at: https://seer.cancer.gov/csr/1975_2015/browse_csr.php?sectionSEL=1&pageSEL=sect_01_table.01.html. Accessed May 24, 2019.
  21. 21.
    Samp RJ, Ansfield FJ. Breast cancer treated with fluorouracil. Survival studies in advanced stages. JAMA. 1966;198:724–30.CrossRefGoogle Scholar
  22. 22.
    Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.CrossRefGoogle Scholar
  23. 23.
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.CrossRefGoogle Scholar
  24. 24.
    Clayton JM, Hancock KM, Butow PN, Tattersall MH, Currow DC. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a lifelimiting illness, and their caregivers. Med J Aust. 2007;186(12 Suppl):S77–108.PubMedGoogle Scholar
  25. 25.
    Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med. 2002;16:297–303.CrossRefGoogle Scholar
  26. 26.
    Oostendorp LJ, Ottevanger PB, van de Wouw AJ, et al. Patients’ preferences for information about the benefits and risks of second-line palliative chemotherapy and their oncologist’s awareness of these preferences. J Cancer Educ. 2016;31:443–8.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  1. 1.NYU Long Island School of MedicineMineolaUSA

Personalised recommendations